News & Updates
Filter by Specialty:
Risk model-based lung cancer screening more economical than USPSTF recommendation
Lung cancer screening based on a risk model is more cost-effective than the 2021 recommendation by the US Preventive Services Task Force (USPSTF), meriting further consideration for the former, reports a recent study.
Risk model-based lung cancer screening more economical than USPSTF recommendation
14 Feb 2023
Shorter treatment regimen feasible for rifampin-resistant TB?
Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.
Shorter treatment regimen feasible for rifampin-resistant TB?
13 Feb 2023
Hormone therapies up ILD events in men with prostate cancer
Hormone therapy drugs, such as bicalutamide, flutamide, nilutamide, goserelin, degarelix, and apalutamide, appear to increase the likelihood of developing interstitial lung disease (ILD) events in patients with prostate cancer, reports a study.
Hormone therapies up ILD events in men with prostate cancer
04 Feb 2023
Does molnupiravir improve outcomes in vaccinated COVID-19 patients?
The addition of molnupiravir to usual care does not reduce hospitalization or death in vaccinated, community-dwelling individuals at high risk of serious outcomes of COVID-19, results of the UK-based PANORAMIC trial showed. However, it may provide other benefits such as reducing time to recovery.